We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · February 01, 2021

ctDNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF-Mutant NSCLC

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients With BRAF-Mutant Metastatic Non–Small Cell Lung Cancer
Clin. Cancer Res 2020 Dec 01;26(23)6242-6253, S Ortiz-Cuaran, L Mezquita, A Swalduz, M Aldea, J Mazieres, C Leonce, C Jovelet, A Pradines, V Avrillon, WR Chumbi Flores, L Lacroix, Y Loriot, V Westeel, M Ngo-Camus, C Tissot, C Raynaud, R Gervais, E Brain, I Monnet, E Giroux Leprieur, C Caramella, C Mahier-Aït Oukhatar, N Hoog-Labouret, F de Kievit, K Howarth, C Morris, E Green, L Friboulet, S Chabaud, JF Guichou, M Perol, B Besse, JY Blay, P Saintigny, D Planchard

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading